Untangling Why DHA Doesn’t Always Help in Alzheimer’s Studies

This review looks at DHA, the main omega-3 fat found in brain tissue, and its possible role in Alzheimer’s disease. Researchers explain how DHA is thought to influence several biological processes linked to Alzheimer’s, including amyloid and tau buildup, synapse function, inflammation, oxidative stress, mitochondrial health, and the balance of fats in brain cell membranes.

Despite this strong mechanistic rationale, and despite population studies generally linking higher DHA levels with better cognitive outcomes, actual clinical trial results have been mixed. The authors suggest this is partly because people who naturally consume more DHA also tend to have healthier diets and lifestyles overall, making it hard to separate DHA’s specific effect.

The review identifies several factors that may explain why some people respond to DHA and others don’t, including how far Alzheimer’s disease has progressed, ApoE ε4 genetic status, sex differences, how much DHA actually reaches the brain, and individual participant characteristics. The authors propose that people at earlier, more modifiable stages of disease with adequate brain DHA levels may be the ones most likely to benefit.

Finally, the paper discusses possible ways to improve future research and outcomes, such as combining DHA with other treatments, using delivery methods designed to better reach the brain, and designing clinical trials that account for these individual differences.